RxDoctor Payments Data

James Grobe, MD

Gastroenterology · Honolulu, HINPI 1538115019

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by AbbVie at 39.6% of the total.

$1,857in general payments, 2019–2025

Across 79 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$736
  • Johnson & Johnson$348
  • Takeda Pharmaceuticals U.S.A., Inc.$307
  • Pfizer$122
  • Ironwood Pharmaceuticals, Inc$96
  • Covidien LP$87
  • plus $162 from 6 others

What the payments were for

  • Food & beverage$1,857100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,857 in reported general payments places this provider in the 55th percentile of 71 gastroenterology providers in Hawaii.

See all gastroenterology providers in Hawaii

Medicare billing

Part B allowed, 2024
$65,454
Medicare patients
200
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$88,010
LinzessLinaclotide30$26,835
Dexlansoprazole DrDexlansoprazole61$25,480
CreonLipase/Protease/Amylase16$20,269
Omeprazole390$15,428
NexiumEsomeprazole Magnesium19$14,261
PentasaMesalamine11$8,753
Lubiprostone16$5,309
Esomeprazole Magnesium42$5,092
Pantoprazole Sodium109$4,031
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg151$3,004
Mesalamine11$2,443
Lansoprazole18$1,360
Peg3350-Sod Sul-Nacl-Kcl-Asb-CPeg3350/Sod Sul/Nacl/Kcl/Asb/C24$1,284
Famotidine32$1,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$736$47,10446 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 71 gastroenterology providers in Hawaii.

Other gastroenterology in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →